High-risk prostate cancer: A disease of genomic instability

被引:26
|
作者
Tapia-Laliena, Maria A. [1 ]
Korzeniewski, Nina [1 ]
Hohenfellner, Markus [1 ]
Duensing, Stefan [1 ]
机构
[1] Heidelberg Univ, Sch Med, Dept Urol, Heidelberg, Germany
关键词
Prostate cancer; Genomic instability; Somatic mutations; DNA damage; Translational therapeutics; Biomarkers; IN-SITU HYBRIDIZATION; DNA-REPAIR; CHROMOSOME INSTABILITY; GENETIC INSTABILITY; ERG; FUSION; REARRANGEMENT; MUTATIONS; DELETIONS; CHROMOTHRIPSIS;
D O I
10.1016/j.urolonc.2014.02.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: In this review, we will discuss the latest advances in our understanding of the relationship between the cellular DNA damage response and genomic instability in prostate cancer and the emerging possibilities to exploit these aberrations as prognostic biomarkers and guides for personalized patient management. Methods: Important findings related to genomic instability in prostate cancer were retrieved from the literature and combined with our own results and a translational perspective. Results: Prostate cancer is characterized by a highly altered genomic landscape with a wide spectrum of genomic alterations, including somatic mutations, copy number alterations (CNAs), gene fusions, complex chromosomal rearrangements, and aneuploidy. In addition, massive DNA damaging events, including chromothripsis and chromoplexy, which can lead to extensive genomic insults in a single step, have been identified. A number of these genomic aberrations have been found to provide prognostic information and can therefore help to identify high-risk patients. In addition, defects in the DNA damage checkpoint and repair machinery can potentially be harnessed for therapeutic purposes. Conclusions: Genomic instability plays a crucial role in the malignant progression of prostate cancer and can be exploited for the development of novel prognostic biomarkers and innovative therapies. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:1101 / 1107
页数:7
相关论文
共 50 条
  • [41] High-risk clinically localised prostate cancer
    Rozet, F.
    Cornu, J-N.
    Cussenot, O.
    Fromont, G.
    Hennequin, C.
    BULLETIN DU CANCER, 2010, 97 (12) : 1517 - 1536
  • [42] High-Risk Prostate Cancer: Radiation or Surgery?
    Stephans, K.
    Tendulkar, R.
    Reddy, C.
    Stephenson, A.
    Klein, E.
    Kupelian, P.
    Ciezki, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S371 - S371
  • [43] Radical Prostatectomy for High-risk Prostate Cancer
    Karnes, R. Jeffrey
    Hatano, Tadashi
    Blute, Michael L.
    Myers, Robert P.
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (01) : 3 - 9
  • [44] Mechanism of Genomic Instability in Cells Infected with the High-Risk Human Papillomaviruses
    Kadaja, Meelis
    Isok-Paas, Helen
    Laos, Triin
    Ustav, Ene
    Ustav, Mart
    PLOS PATHOGENS, 2009, 5 (04)
  • [45] The management of high-risk prostate cancer in 2008
    Yves Fradet
    World Journal of Urology, 2008, 26 : 203 - 203
  • [46] Prostate cancer screening in high-risk patients
    Feingold, RM
    ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (08) : 1204 - 1204
  • [47] High-risk prostate cancer. Review
    Rozet, F.
    Hennequin, C.
    Fromont, G.
    Mongiat-Artus, P.
    Bastide, C.
    Beuzeboc, P.
    Cormier, L.
    Eiss, D.
    Peyrornaure, M.
    Richaud, P.
    Salomon, L.
    Soulie, M.
    PROGRES EN UROLOGIE, 2011, 21 (13): : 901 - 908
  • [48] The role for surgeryin high-risk prostate cancer
    Lanchon, Cecilia
    Shariat, Shahrokh F.
    Roupret, Morgan
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2015, 165 (19-20) : 395 - 400
  • [49] Postprostatectomy radiotherapy for high-risk prostate cancer
    Mayer, R
    Pummer, K
    Quehenberger, F
    Mayer, E
    Fink, L
    Hackl, A
    UROLOGY, 2002, 59 (05) : 732 - 739
  • [50] High-risk prostate cancer: The rationale for brachytherapy
    Blasko, John C.
    ONCOLOGY-NEW YORK, 2008, 22 (09): : 1016 - 1017